comparemela.com

Latest Breaking News On - American society of microbiology - Page 34 : comparemela.com

Federation of European Microbiological Societies and American Society of Microbiology announce World Microbe Forum

Federation of European Microbiological Societies and American Society of Microbiology announce World Microbe Forum Introducing World Microbe Forum, a Digital Meeting of the Microbial Sciences.   Despite physical distancing resulting from the pandemic, microbial scientists will convene digitally for a unique gathering covering cutting-edge, interdisciplinary microbial sciences research. Recognizing that microbial sciences, just like microbes, know no borders, the Federation of European Microbiological Societies (FEMS) and the American Society of Microbiology (ASM) are excited to announce the World Microbe Forum –  a collaboration bringing two of the biggest events in the microbial sciences, ASM Microbe and FEMS2021, together. The forum will take place from 20-24 June 2021. 

Research teams in Montreal, Toronto looking at how COVID-19 impacts immunity

Research teams in Montreal, Toronto looking at how COVID-19 impacts immunity Last Updated Dec 17, 2020 at 1:23 pm MDT FILE Specimens to be tested for COVID-19 are seen at a lab, in Surrey, B.C., on Thursday, March 26, 2020. THE CANADIAN PRESS/Darryl Dyck MONTREAL – Research from two university teams is shedding a little bit of light on why COVID-19 patients have more severe side effects than those with the regular seasonal flu. The teams, from the Université de Montréal and the University of Toronto are backed by Canada’s COVID-19 Immunity Task Force (CITF). The Toronto team recently had its findings shared in the Journal of Immunology.

Why Algernon Pharmaceuticals could have the leading therapeutic drug for the COVID-19 pandemic

Dec 11, 2020 Malin Dunfors, Market One Media Algernon Pharmaceuticals has been hard at work repurposing Ifenprodil for those affected by idiopathic pulmonary fibrosis, chronic cough, as well as COVID-19. , Market One Media New England Journal of Medicine reports that four repurposed antiviral drugs tested in 11,330 patients hospitalized with COVID-19 showed little to no effect December’s release of interim data from the company’s Ifenprodil COVID-19 multinational trial marks important milestone The IPF (Idiopathic Pulmonary Fibrosis) market is expected to grow to USD$3.6 billion by 2029 In mid-January, scientists published the genetic sequence of the coronavirus, thought to be behind the outbreak of a new form of pneumonia. Not long after, the hunt for a potential coronavirus vaccine began.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.